Prime Medicine, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.6M | $3.0M | $0 | $0 | $0 |
| Research and development | $160.6M | $155.3M | $147.9M | $86.7M | $70.5M |
| Operating expenses | $213.0M | $205.4M | $204.8M | $116.5M | $84.5M |
| Operating income | -$208.3M | -$202.5M | -$204.8M | -$116.5M | -$84.5M |
| Income tax expense | $0 | $0 | -$279,000 | -$948,000 | -$486,000 |
| Net income | -$201.1M | -$195.9M | -$198.1M | -$121.8M | -$165.4M |
| Balance Sheet | |||||
| Cash and equivalents | $63.0M | $182.5M | $41.6M | $187.6M | $185.4M |
| Current assets | $181.3M | $211.9M | $143.0M | $296.6M | $270.6M |
| Total assets | $342.7M | $297.5M | $193.9M | $360.3M | $301.9M |
| Current liabilities | $37.4M | $38.0M | $56.4M | $26.7M | $58.0M |
| Total liabilities | $221.9M | $144.4M | $60.8M | $44.0M | $62.3M |
| Stockholders' equity | $120.9M | $153.1M | $133.1M | $316.3M | -$156.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$162.6M | -$122.9M | -$165.4M | -$131.8M | -$34.1M |
| Depreciation and amortization | $7.3M | $6.1M | $4.7M | $2.2M | $568,000 |
| Stock-based compensation | $29.3M | $26.1M | $13.9M | $6.5M | $1.7M |
| Capital expenditure | $4.5M | $7.3M | $8.7M | $16.1M | $4.2M |
| Free cash flow | -$167.1M | -$130.2M | -$174.1M | -$147.9M | -$38.2M |
Shares outstanding 180.6M · Free float 52.4%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.